Prostate Cancer Stocks List



Recent Signals

Date Stock Signal Type
2021-05-05 ABBV New 52 Week Closing High Bullish
2021-05-05 ABBV Upper Bollinger Band Walk Strength
2021-05-05 ABBV New 52 Week High Strength
2021-05-05 ABBV NR7 Range Contraction
2021-05-05 ACHV MACD Bearish Signal Line Cross Bearish
2021-05-05 ACHV Fell Below 200 DMA Bearish
2021-05-05 ADMP Fell Below 200 DMA Bearish
2021-05-05 ADMP Fell Below 50 DMA Bearish
2021-05-05 ADMP Volume Surge Other
2021-05-05 AEZS Fell Below 20 DMA Bearish
2021-05-05 AFMD 1,2,3 Pullback Bullish Bullish Swing Setup
2021-05-05 AFMD Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-05-05 AFMD 20 DMA Support Bullish
2021-05-05 AMGN New Uptrend Bullish
2021-05-05 AMGN Cup with Handle Other
2021-05-05 AYTU Lower Bollinger Band Walk Weakness
2021-05-05 AYTU New 52 Week Low Weakness
2021-05-05 AYTU New 52 Week Closing Low Bearish
2021-05-05 BLCM 20 DMA Support Bullish
2021-05-05 BNR Bollinger Band Squeeze Range Contraction
2021-05-05 BNR Bullish Engulfing Bullish
2021-05-05 CBLI 20 DMA Resistance Bearish
2021-05-05 CRDF Volume Surge Other
2021-05-05 CRDF Pocket Pivot Bullish Swing Setup
2021-05-05 CRDF Expansion Pivot Buy Setup Bullish Swing Setup
2021-05-05 CRDF 180 Bullish Setup Bullish Swing Setup
2021-05-05 CRDF Crossed Above 50 DMA Bullish
2021-05-05 EDAP Slingshot Bearish Bearish Swing Setup
2021-05-05 EDAP 180 Bearish Setup Bearish Swing Setup
2021-05-05 ENDP Jack-in-the-Box Bearish Bearish Swing Setup
2021-05-05 ENDP Bollinger Band Squeeze Range Contraction
2021-05-05 ENDP 200 DMA Resistance Bearish
2021-05-05 EXEL Pocket Pivot Bullish Swing Setup
2021-05-05 EXEL 20 DMA Resistance Bearish
2021-05-05 EXEL Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-05-05 HARP Stochastic Sell Signal Bearish
2021-05-05 IONS Wide Range Bar Range Expansion
2021-05-05 IONS New 52 Week Low Weakness
2021-05-05 IONS New 52 Week Closing Low Bearish
2021-05-05 IONS 20 DMA Resistance Bearish
2021-05-05 IONS Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-05-05 IONS Reversal New Lows Setup Bearish Swing Setup
2021-05-05 ISR NR7 Range Contraction
2021-05-05 ISR 200 DMA Resistance Bearish
2021-05-05 ISR Narrow Range Bar Range Contraction
2021-05-05 JAZZ Pocket Pivot Bullish Swing Setup
2021-05-05 JAZZ Expansion Pivot Buy Setup Bullish Swing Setup
2021-05-05 JAZZ 180 Bullish Setup Bullish Swing Setup
2021-05-05 JAZZ MACD Bullish Signal Line Cross Bullish
2021-05-05 JAZZ Wide Range Bar Range Expansion
2021-05-05 JAZZ MACD Bullish Centerline Cross Bullish
2021-05-05 JAZZ Crossed Above 50 DMA Bullish
2021-05-05 JAZZ Crossed Above 20 DMA Bullish
2021-05-05 MYGN 180 Bearish Setup Bearish Swing Setup
2021-05-05 MYGN Fell Below 50 DMA Bearish
2021-05-05 MYGN Fell Below 20 DMA Bearish
2021-05-05 MYGN Bearish Engulfing Bearish
2021-05-05 MYGN Wide Range Bar Range Expansion
2021-05-05 MYGN Expansion Pivot Sell Setup Bearish Swing Setup
2021-05-05 MYOV NR7 Range Contraction
2021-05-05 NUVB 50 DMA Resistance Bearish
2021-05-05 NUVB Crossed Above 20 DMA Bullish
2021-05-05 NUVB NR7 Range Contraction
2021-05-05 NYMX Calm After Storm Range Contraction
2021-05-05 OPK Bollinger Band Squeeze Range Contraction
2021-05-05 OPK Spinning Top Other
2021-05-05 PDSB Wide Range Bar Range Expansion
2021-05-05 PDSB Bollinger Band Squeeze Range Contraction
2021-05-05 PDSB MACD Bearish Signal Line Cross Bearish
2021-05-05 PDSB 50 DMA Support Bullish
2021-05-05 PDSB Bearish Engulfing Bearish
2021-05-05 PDSB Fell Below 20 DMA Bearish
2021-05-05 PROF Slingshot Bearish Bearish Swing Setup
2021-05-05 RAIN NR7 Range Contraction
2021-05-05 SGEN Lower Bollinger Band Walk Weakness
2021-05-05 SGEN NR7 Range Contraction
2021-05-05 SGEN New 52 Week Closing Low Bearish
2021-05-05 SLRX 20 DMA Resistance Bearish
2021-05-05 SNY Stochastic Reached Oversold Weakness
2021-05-05 SNY Narrow Range Bar Range Contraction
2021-05-05 SNY Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-05-05 SPPI Bollinger Band Squeeze Range Contraction
2021-05-05 VACC New 52 Week Closing Low Bearish
2021-05-05 VACC New 52 Week Low Weakness
2021-05-05 VACC Hot IPO Pullback Bullish Swing Setup
2021-05-05 VERU Slingshot Bearish Bearish Swing Setup
2021-05-05 VERU Volume Surge Other
2021-05-05 VERU 20 DMA Resistance Bearish
2021-05-05 VERU Wide Range Bar Range Expansion
2021-05-05 VERU Pocket Pivot Bullish Swing Setup
2021-05-05 XOMA Bollinger Band Squeeze Range Contraction
2021-05-05 XOMA Stochastic Reached Oversold Weakness

Recent News for Prostate Cancer Stocks

Date Stock Title
May 5 IONS Ionis Pharmaceuticals, Inc. (IONS) CEO Brett Monia on Q1 2021 Results - Earnings Call Transcript
May 5 EXEL Exelixis Q1 Earnings Preview
May 5 ENDP Endo Q1 2021 Earnings Preview
May 5 JAZZ Jazz Pharmaceuticals' Acquisition of GW Pharmaceuticals Closes
May 5 ABBV Diamond Hill Capital Reveals Top 1st-Quarter Trades
May 5 IONS Ionis to host 2021 virtual annual meeting of stockholders
May 5 MYGN Myriad Genetics CEO Paul J. Diaz to Present at Bank of America Securities 2021 Virtual Health Care Conference
May 5 ABBV 'Halftime Report' Traders Weigh In On AbbVie, Chewy And More
May 5 VERU Veru Inc. (VERU) Expected to Beat Earnings Estimates: Should You Buy?
May 5 PROF Analysts Estimate PROFOUND MEDICL (PROF) to Report a Decline in Earnings: What to Look Out for
May 5 SNY CDC’s projection of U.S. COVID-19 surge is a ‘crystal ball’: Doctor
May 5 IONS Ionis Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 5 SNY Glaxo Defends Strategy in Face of Elliott Management Stake
May 5 IONS Ionis Pharmaceuticals Drops on Wide Quarterly Loss
May 5 JAZZ Jazz closes acquisition of GW Pharmaceuticals
May 5 JAZZ Jazz Pharma (JAZZ) Q1 Earnings Beat, Sales Miss, Stock Down
May 5 AMGN FDA accepts Amgen's Otezla application in plaque psoriasis
May 5 MYGN Myriad Genetics (MYGN) Beats on Q1 Earnings and Revenues
May 5 JAZZ Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc
May 5 VERU Veru's Stock Jumps As Enobosarm Shows Clinical Benefit In Heavily Pretreated Breast Cancer Patients

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other areas of the body, particularly the bones and lymph nodes. It may initially cause no symptoms. In later stages, it can lead to difficulty urinating, blood in the urine or pain in the pelvis, back, or when urinating. A disease known as benign prostatic hyperplasia may produce similar symptoms. Other late symptoms may include feeling tired due to low levels of red blood cells.Factors that increase the risk of prostate cancer include older age, a family history of the disease, and race. About 99% of cases occur in males over the age of 50. Having a first-degree relative with the disease increases the risk two to threefold. In the United States, it is more common in the African American population than the White American population. Other factors that may be involved include a diet high in processed meat, red meat or milk products or low in certain vegetables. An association with gonorrhea has been found, but a reason for this relationship has not been identified. An increased risk is associated with the BRCA mutations. Prostate cancer is diagnosed by biopsy. Medical imaging may then be done to determine if the cancer has spread to other parts of the body.Prostate cancer screening is controversial. Prostate-specific antigen (PSA) testing increases cancer detection, but it is controversial regarding whether it improves outcomes. Informed decision making is recommended when it comes to screening among those 55 to 69 years old. Testing, if carried out, is more reasonable in those with a longer life expectancy. While 5α-reductase inhibitors appear to decrease low-grade cancer risk, they do not affect high-grade cancer risk and thus are not recommended for prevention. Supplementation with vitamins or minerals does not appear to affect the risk.Many cases are managed with active surveillance or watchful waiting. Other treatments may include a combination of surgery, radiation therapy, hormone therapy or chemotherapy. When it only occurs inside the prostate, it may be curable. In those in whom the disease has spread to the bones, pain medications, bisphosphonates and targeted therapy, among others, may be useful. Outcomes depend on a person's age and other health problems as well as how aggressive and extensive the cancer is. Most men with prostate cancer do not end up dying from the disease. The 5-year survival rate in the United States is 99%. Globally, it is the second most common type of cancer and the fifth leading cause of cancer-related death in men. In 2012, it occurred in 1.1 million men and caused 307,000 deaths. It was the most common cancer in males in 84 countries, occurring more commonly in the developed world. Rates have been increasing in the developing world. Detection increased significantly in the 1980s and 1990s in many areas due to increased PSA testing. Studies of males who died from unrelated causes have found prostate cancer in 30% to 70% of those over age 60.

More about Prostate Cancer
Browse All Tags